Heart disease claims approximately 655,000 American lives each year, with coronary heart disease accounting for the largest share of cardiovascular deaths at 85.2 per 100,000 population. This staggering mortality burden underscores why breakthrough therapies are critically needed.
Current treatments, while effective at slowing disease progression, cannot reverse the underlying tissue damage that drives heart failure in 6.2 million U.S. adults. A new NEJM editorial examines how emerging cardiac patch therapies could address this gap by promoting actual tissue regeneration rather than symptom management alone.
These patch-based interventions represent a promising frontier in regenerative medicine, offering potential for patients who have exhausted conventional treatment options and highlighting the real-world impact of continued investment in cardiac research.
Read the full article on GMJ Newsroom.
Was this article helpful?
